Legend Biotech (LEGN) Stock Price, News & Analysis

+0.39 (+0.83%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.81 million shs
Average Volume
919,694 shs
Market Capitalization
$8.63 billion
P/E Ratio
Dividend Yield
Price Target

Legend Biotech MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.92 Rating Score
75.5% Upside
$83.26 Price Target
Short Interest
5.49% of Shares Sold Short
Dividend Strength
News Sentiment
0.41mentions of Legend Biotech in the last 14 days
Based on 26 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.43) to $0.08 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.47 out of 5 stars

Medical Sector

465th out of 909 stocks

Pharmaceutical Preparations Industry

208th out of 424 stocks

LEGN stock logo

About Legend Biotech Stock (NASDAQ:LEGN)

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

LEGN Stock Price History

LEGN Stock News Headlines

Elon Musk’s Controversial New Project: “Apollo”
Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...
Legend Biotech (NASDAQ:LEGN) Reaches New 1-Year Low at $49.13
Elon Musk’s Controversial New Project: “Apollo”
Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...
LEGN Quantitative Stock Analysis
Legend Biotech is Now Oversold (LEGN)
See More Headlines
Receive LEGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
12 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$285.14 million
Book Value
$6.88 per share


Free Float
Market Cap
$8.63 billion
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Ying Huang Ph.D. (Age 51)
    CEO & Director
  • Ms. Lori A. Macomber CPA (Age 53)
    Chief Financial Officer
  • Mr. Doug Wallace
    Vice President of Global Operations
  • Dr. Guowei Fang Ph.D.
    Chief Scientific Officer & Head of Business Development
  • Joanne Choi
    Senior Manager of Investor Relations
  • Mr. James Pepin J.D.
    General Counsel
  • Deborah Wong
    Executive Director of Strategic Marketing & Corporate Communications
  • Ms. Elaine Qian
    VP & Global Head of Human Resources
  • Dr. Yuhong Qiu Ph.D.
    Senior Vice President of Global Regulatory Affairs
  • Mr. Steven J. Gavel
    Senior Vice President of Commercial Development, US & Europe

LEGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Legend Biotech stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LEGN shares.
View LEGN analyst ratings
or view top-rated stocks.

What is Legend Biotech's stock price target for 2024?

12 brokers have issued twelve-month price objectives for Legend Biotech's stock. Their LEGN share price targets range from $64.00 to $94.00. On average, they expect the company's share price to reach $83.26 in the next year. This suggests a possible upside of 75.5% from the stock's current price.
View analysts price targets for LEGN
or view top-rated stocks among Wall Street analysts.

How have LEGN shares performed in 2024?

Legend Biotech's stock was trading at $60.17 on January 1st, 2024. Since then, LEGN shares have decreased by 21.1% and is now trading at $47.45.
View the best growth stocks for 2024 here

When is Legend Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our LEGN earnings forecast

How can I listen to Legend Biotech's earnings call?

Legend Biotech will be holding an earnings conference call on Monday, May 13th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Legend Biotech's earnings last quarter?

Legend Biotech Co. (NASDAQ:LEGN) posted its earnings results on Monday, March, 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.30. The business had revenue of $76.50 million for the quarter, compared to analyst estimates of $95.63 million. Legend Biotech had a negative trailing twelve-month return on equity of 37.19% and a negative net margin of 181.75%. The business's revenue was up 177.2% on a year-over-year basis.

What other stocks do shareholders of Legend Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON), QUALCOMM (QCOM), Applied Materials (AMAT), DocuSign (DOCU) and Etsy (ETSY).

When did Legend Biotech IPO?

Legend Biotech (LEGN) raised $350 million in an initial public offering on Friday, June 5th 2020. The company issued 18,400,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies acted as the underwriters for the IPO.

Who are Legend Biotech's major shareholders?

Legend Biotech's stock is owned by many different institutional and retail investors. Top institutional shareholders include Matthews International Capital Management LLC (0.41%), Sumitomo Mitsui Trust Holdings Inc. (0.09%), Handelsinvest Investeringsforvaltning (0.00%) and IFM Investors Pty Ltd (0.00%).

How do I buy shares of Legend Biotech?

Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LEGN) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners